The "Learned Intermediary": The Role of the Psychiatric Interventionist in Product Liability Lawsuits.

IF 1.8 4区 医学 Q3 BEHAVIORAL SCIENCES Journal of Ect Pub Date : 2025-06-01 Epub Date: 2025-02-10 DOI:10.1097/YCT.0000000000001122
William V McCall, Rebecca E Strickland
{"title":"The \"Learned Intermediary\": The Role of the Psychiatric Interventionist in Product Liability Lawsuits.","authors":"William V McCall, Rebecca E Strickland","doi":"10.1097/YCT.0000000000001122","DOIUrl":null,"url":null,"abstract":"<p><strong>Abstract: </strong>Malpractice lawsuits brought by patient-plaintiffs alleging damages from medications or medical devices may entangle both the prescriber and the biomedical manufacturer. In this scenario, the prescriber may be viewed as a defendant, or alternatively as a \"learned intermediary\" (LI) between the patient and biomedical company. Recent legal actions in the United States involving manufacturers of electroconvulsive therapy devices have invoked the principle of the LI in the arguments. The plaintiff argued that the manufacturer held a major responsibility for providing to device operators warnings which lack scientific basis. This commentary will describe the legal concepts of the LI, and we will argue that the prescriber's duty to the patient is to provide relevant warnings with a scientific grounding, based upon the sum total of the prescriber's education. The courts opined that the conveyance of benefit and risk information to the patient should reflect what is \"known or knowable in light of the generally recognized and prevailing best scientific and medical knowledge available .\" Himes v. Somatics, LLC, 16 Cal. 5th 209, 222, 549 P.3d 916, 923 (2024) (emphasis added).</p>","PeriodicalId":54844,"journal":{"name":"Journal of Ect","volume":" ","pages":"150-151"},"PeriodicalIF":1.8000,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Ect","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/YCT.0000000000001122","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/2/10 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"BEHAVIORAL SCIENCES","Score":null,"Total":0}
引用次数: 0

Abstract

Abstract: Malpractice lawsuits brought by patient-plaintiffs alleging damages from medications or medical devices may entangle both the prescriber and the biomedical manufacturer. In this scenario, the prescriber may be viewed as a defendant, or alternatively as a "learned intermediary" (LI) between the patient and biomedical company. Recent legal actions in the United States involving manufacturers of electroconvulsive therapy devices have invoked the principle of the LI in the arguments. The plaintiff argued that the manufacturer held a major responsibility for providing to device operators warnings which lack scientific basis. This commentary will describe the legal concepts of the LI, and we will argue that the prescriber's duty to the patient is to provide relevant warnings with a scientific grounding, based upon the sum total of the prescriber's education. The courts opined that the conveyance of benefit and risk information to the patient should reflect what is "known or knowable in light of the generally recognized and prevailing best scientific and medical knowledge available ." Himes v. Somatics, LLC, 16 Cal. 5th 209, 222, 549 P.3d 916, 923 (2024) (emphasis added).

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
“学习中介”:精神科介入医师在产品责任诉讼中的角色。
摘要:由患者原告提起的因药品或医疗器械损害赔偿的医疗事故诉讼,可能使处方方和生物医药生产企业都陷入困境。在这种情况下,开处方者可能被视为被告,或者作为患者和生物医药公司之间的“学习中介”(LI)。最近在美国涉及电惊厥治疗设备制造商的法律诉讼中,在辩论中援引了LI原则。原告辩称,制造商对向设备操作员提供缺乏科学依据的警告负有主要责任。这篇评论将描述LI的法律概念,我们将论证开处方者对患者的责任是根据开处方者所受教育的总和,提供具有科学依据的相关警告。法院认为,向患者传达利益和风险信息应反映“根据普遍公认和普遍存在的最佳科学和医学知识已知或可知的内容”。Himes诉Somatics, LLC, 16 Cal. 5th 209, 222, 549 P.3d 916, 923(2024)(重点添加)。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Journal of Ect
Journal of Ect 医学-行为科学
CiteScore
3.70
自引率
20.00%
发文量
154
审稿时长
6-12 weeks
期刊介绍: ​The Journal of ECT covers all aspects of contemporary electroconvulsive therapy, reporting on major clinical and research developments worldwide. Leading clinicians and researchers examine the effects of induced seizures on behavior and on organ systems; review important research results on the mode of induction, occurrence, and propagation of seizures; and explore the difficult sociological, ethical, and legal issues concerning the use of ECT.
期刊最新文献
Role of Anesthesia in ECT for Major Depressive Disorder. Practical Steps: Using Electroconvulsive Therapy in Patients With Neurodevelopmental Disorders and Catatonia. Electroconvulsive Therapy for Treatment-Resistant Poststroke Depression Following Flow Diversion-Related In-Stent Thrombosis. Variability in Real-World Electroconvulsive Therapy (ECT) Practice: Is Perfection the Enemy of the Good? Rethinking Seizure Termination: A Possible Paradigm Shift in Understanding a Primary Mechanism of ECT.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1